Document is current
Any future updates will be listed below
-
Authors
Vu, Mai Ha https://orcid.org/0000-0002-9702-226X
Akbar, Rahmad https://orcid.org/0000-0002-6692-0876
Robert, Philippe A. https://orcid.org/0000-0003-1345-5015
Swiatczak, Bartlomiej https://orcid.org/0000-0001-6767-3064
Sandve, Geir Kjetil https://orcid.org/0000-0002-4959-1409
Greiff, Victor https://orcid.org/0000-0003-2622-5032
Haug, Dag Trygve Truslew https://orcid.org/0000-0001-5275-8073
-
Funding
Funding for this research was provided by:
University of Oslo | Livsvitenskap, Universitetet i Oslo
Norges Forskningsråd (311341, 300740, 311341)
Stiftelsen Kristian Gerhard Jebsen
Leona M. and Harry B. Helmsley Charitable Trust (2019PG-T1D011)
EC | Horizon 2020 Framework Programme (825821)
Kreftforeningen (215817)
- License Information
-
More Information
Article History
Received: 7 July 2022
Accepted: 2 March 2023
First Online: 6 April 2023
Competing interests
: V.G. declares advisory board positions in aiNET GmbH, Enpicom B.V, Specifica Inc, Adaptyv Biosystems, EVQLV and Omniscope. V.G. is a consultant for Roche/Genentech, immunai and Proteinea. The remaining authors declare no competing interests.
